Male sex adversely impacts survival and myeloid malignancy risk in MGUS: a real-world population-based study

Monoclonal gammopathy of undetermined significance (MGUS) is a common plasma cell disorder with well described risks of progression to myeloma and lymphoplasmacytic lymphoma. Using data from an established UK population-based cohort of haematological malignancies and premalignancies, we investigated patient and disease characteristics, subsequent haematological malignancy, and survival in 4651 people diagnosed with MGUS 2005-2019. The 5-year net (relative) survival (disease-specific estimate of the probability of survival) of MGUS patients was 87.8% (95% Confidence Interval 85.9-89.7), with males (83.8%; 95% CI 81.0-86.6) more affected than females (92.2%; 95% CI 89.7-94.7). The proportion of subsequent haematological malignancies was also higher in males than females (8.8% versus 5.3%; P.

Authors

Institutions

Publication Details

Journal
Haematologica
Published
2026-01-29
DOI
https://doi.org/10.3324/haematol.2025.289200
Primary Topic
Multiple Myeloma Research and Treatments
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Male sex adversely impacts survival and myeloid malignancy risk in MGUS: a real-world population-based study

Christopher Parrish, S. Crouch, A. Rawstron, Debra Howell et al.
Haematologica
Multiple Myeloma Research and Treatments
article

Male sex adversely impacts survival and myeloid malignancy risk in MGUS: a real-world population-based study

Christopher Parrish, S. Crouch, A. Rawstron, Debra Howell, Timothy Bagguley, Daniel Painter, Reuben Tooze, Russell Patmore, Catherine Cargo, Eve Roman, Gordon Cook, Frances Seymour, Ruth De Tute, Alexandra Smith
article en

Abstract

Monoclonal gammopathy of undetermined significance (MGUS) is a common plasma cell disorder with well described risks of progression to myeloma and lymphoplasmacytic lymphoma. Using data from an established UK population-based cohort of haematological malignancies and premalignancies, we investigated patient and disease characteristics, subsequent haematological malignancy, and survival in 4651 people diagnosed with MGUS 2005-2019. The 5-year net (relative) survival (disease-specific estimate of the probability of survival) of MGUS patients was 87.8% (95% Confidence Interval 85.9-89.7), with males (83.8%; 95% CI 81.0-86.6) more affected than females (92.2%; 95% CI 89.7-94.7). The proportion of subsequent haematological malignancies was also higher in males than females (8.8% versus 5.3%; P.

Haematologica
Castle Hill Hospital (GB), Yorkshire Cancer Research (GB), St James's University Hospital (GB), NIHR Research Delivery Network (GB), University of York (GB)
Amgen, Pfizer, Sanofi, Gilead Sciences, Celgene, Cancer Research UK, National Institute for Health and Care Research, Department of Health and Social Care, Blood Cancer UK, Leeds Biomedical Research Centre
Good health and well-being
Openalex Percentile: Top 76%
Multiple Myeloma Research and Treatments
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.